Thelansis

Adult T-Cell Lymphoma/Leukaemia (ATL) Market Outlook Thelansis’s “Adult T-Cell Lymphoma/Leukaemia (ATL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult T-Cell Lymphoma/Leukaemia (ATL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the g...

Adult T-Cell Lymphoma/Leukaemia (ATL) Market Outlook Thelansis’s “Adult T-Cell Lymphoma/Leukaemia (ATL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult T-Cell Lymphoma/Leukaemia (ATL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Adult T-Cell Lymphoma/Leukaemia (ATL) Overview Adult T-cell lymphoma/leukaemia (ATL) is a rare lymphoproliferative neoplasm of mature CD4+ CD25+ T cells caused by infection with the retrovirus human T-lymphotropic virus type 1 (HTLV-1). The aggressive subtypes of ATL carry some of the poorest prognoses of any of the non-Hodgkin lymphomas. In an extensive retrospective analysis, patients with A...

 Adult T-cell lymphoma/leukaemia (ATL) is a rare lymphoproliferative neoplasm of mature CD4+ CD25+ T cells caused by infection with the retrovirus human T-lymphotropic virus type 1 (HTLV-1). The aggressive subtypes of ATL carry some of the poorest prognoses of any of the non-Hodgkin lymphomas. In an extensive retrospective analysis, patients with ATL had 5-year failure-free and overall survival (OS) of only 12% and 14%, respectively. However, the clinical course can vary with this disease's chronic and smouldering variants. In patients without histologically proven tumor lesions, at least 5% of circulating abnormal T lymphocytes are required to diagnose ATL. These cells typically express the surface T-cell lymphocytic markers CD2, CD4, CD5, CD29, CD45RO, and T-cell receptor (TCR) αβ and are usually negative for CD7, CD8, and CD26 and show reduced CD3 expression. HLA-DP, DQ, DR, and interleukin-2R (CD25) lymphocytic activation markers are always present, whereas terminal deoxynucleo...